“Increasing Adoption of Biomarker-Based Tests and Genetic Testing”
The global Non-Hodgkin Lymphoma (NHL) diagnostics market is witnessing significant growth, driven by advancements in diagnostic technologies such as Next Generation Sequencing (NGS) and Fluorescent In Situ Hybridization (FISH), which improve early detection and precision in identifying lymphoma subtypes. A key trend in the market is the increasing adoption of biomarker-based tests and genetic testing for personalized cancer care, which helps tailor treatment strategies based on individual tumor profiles. For instance, Immunohistochemistry is widely used to differentiate aggressive from indolent lymphomas, allowing for more targeted therapy. The growing focus on predictive diagnostics in hospitals and cancer research centers is bolstered by innovations in platform-based products and kits and reagents. Such trend, combined with a rising preference for screening and prognostic applications, especially in stage I and II cancers, is expected to further drive market expansion, as early-stage detection becomes a critical factor in improving patient outcomes.
